Markets › United States › NAS › TLX

Telix Pharmaceuticals Ltd

NAS:TLXHealthcarenasdaq_composite

$11.19+4.19%LiveIn session · ≈ AED 41.10 · Market cap $3.87B · Next earnings Fri 19 Feb

Ratio	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	Current · undated	YoY
Gross margin	61.2%	66.5%	59.3%	62.6%	65.1%	53.1%	—	—
Operating margin	−847.7%	−1,069.6%	−57.4%	3.2%	10.5%	2.2%	2.2%	+0.0 pts
Net margin	−861.1%	−1,059.9%	−65.0%	1.0%	6.4%	−0.9%	−0.9%	+0.0 pts
EBITDA margin	−862.1%	−922.5%	−58.0%	4.6%	12.5%	6.6%	—	—
Return on equity	−56.8%	−3,730.8%	−130.1%	3.5%	8.8%	−1.7%	−1.7%	+0.0 pts
Return on assets	−28.4%	−73.3%	−40.8%	1.3%	3.3%	−0.6%	−0.6%	+0.0 pts
Return on capital employed	−32.1%	−113.1%	−54.1%	6.6%	6.9%	1.9%	—	—
Debt / equity	0.0×	1.2×	0.1×	0.1×	1.0×	1.1×	1.1×	+0.0%
Debt / assets	1.4%	2.3%	4.1%	4.4%	38.3%	39.5%	—	—
Interest coverage	−37.6×	−415.2×	−226.4×	1.8×	3.8×	0.5×	—	—
Current ratio	4.7×	1.3×	2.0×	1.4×	2.8×	1.4×	1.4×	+0.0%
Quick ratio	4.7×	1.2×	2.0×	1.3×	2.7×	1.3×	—	—
Cash ratio	3.9×	0.6×	1.4×	0.8×	2.1×	0.6×	0.6×	+0.0%
Asset turnover	0.0×	0.1×	0.6×	1.3×	0.5×	0.7×	—	—
Inventory turnover	3.2×	11.2×	11.3×	10.9×	7.2×	10.2×	—	—
Receivables turnover	0.4×	0.4×	5.1×	6.3×	4.9×	5.8×	—	—
Dividend payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—